Drugs / RNDP-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07106021 | Jul 2025 → Sep 2027 expected | Parkinson disease | Kenai Therapeutics | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-07 | Kenai Therapeutics | Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 kenaitx.com ↗ |
| 2025-12-15 | Kenai Therapeutics | Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson’s Disease kenaitx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNDP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07106021 ↗ |
| Modality | Cell therapy | “Intraputamenal Dopaminergic Stem Cell Transplants” NCT07106021 ↗ |
| Route | Other | “will be implanted into the brain” NCT07106021 ↗ |